Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

116.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 280
Open 116.62
Bid (Size) 113.00 (3)
Ask (Size) 121.00 (1)
Prev. Close 116.62
Today's Range 116.62 - 116.62
52wk Range 75.56 - 139.13
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years. 
Via The Motley Fool

Performance

YTD
+33.6%
+33.6%
1 Month
+4.9%
+4.9%
3 Month
+13.3%
+13.3%
6 Month
-7.4%
-7.4%
1 Year
+28.2%
+28.2%

More News

Read More
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Where Axsome Therapeutics Stands With Analysts
Via Benzinga
Earnings Scheduled For August 4, 2025
Via Benzinga
A Look at Axsome Therapeutics's Upcoming Earnings Report
Via Benzinga
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
Via Benzinga
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
Via Benzinga
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading
Via Chartmill
Axsome (AXSM) Q2 Revenue Soars 72%
Via The Motley Fool
Topics Intellectual Property
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Via The Motley Fool
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Where Axsome Therapeutics Stands With Analysts
Via Benzinga
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
Via Benzinga
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
Via Benzinga

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 116.62
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 09/17/25 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 5.50B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.